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A B S T R A C T
Differentiated thyroid cancers include papillary and follicular carcinomas, both originating from follicular epithe-
lium. Treatment of choice is usually total or near total thyroidectomy, followed by ablative radioiodine 131I treatment,
and by the long term administration of thyroid hormone. Despite its excellent prognosis, recurrent disease does occur in
approximately 20–40% of patients. Guidelines for the follow-up management of differentiated thyroid cancer are com-
monly based on circulating thyrogobulin measurement in the complete absence of eutopic thyroid tissue. A retrospective
review was conducted on 116 patients (66 papillary and 50 follicular carcinoma, mean age 51.2 years) who had under-
gone total or near total thyroidectomy and radioactive iodine remnant ablation. Serum thyroglobulin (Tg) and anti-thy-
roglobulin antibodies (TgAb) levels were measured preoperatively, 1 month after thyroidectomy (before 131I treatment)
and 6 and 12 months after ablation therapy (Tg1, TgAb1 and Tg2, TgAb2, respectively). During one year of follow-up, in
a total of 24 patients (21%) recurrent disease were confirmed by ultrasonography and whole-body-scanning, mostly. It
was found significant correlation between serum Tg levels (measured preoperatively and postoperatively) and recurrent
diseases (p<0.05), while serum TgAb levels did not have any statistical significance. However, in multivariate regression
analysis only Tg levels measured 12 months after the therapy (Tg2) remained a significant predictor of recurrent disease
(p=0.008). Although a high Tg level before surgery does not indicate that tumor is present, in the postoperative period
and after ablative therapy Tg has proven predictive value because stimulated Tg levels above 10ng/ml confirmed that in-
dicate residual or recurrent cancer, and its periodically measurements is recommended.
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Introduction
Differentiated thyroid cancer (DTC), arising from
thyroid follicular epithelial cells, accounts for approxi-
mately 90% of all thyroid cancer1. There are two major
forms of DTC: papillary and follicular. Papillary cancer is
the most common type of thyroid cancer (about 85%)2,
which outcome is variable. The lymph-node involvement
is frequent and early in papillary cancer, with specific lo-
calization to lymph nodes next to the trachea or wind-
pipe, called the paratracheal lymph nodes3. Vascular in-
vasion is rare, and distant metastases are observed in
less than 10% of cases4–6. Generally, the prognosis of pap-
illary cancer is excellent. Follicular cancer is less fre-
quent than papillary (5% to 15% of thyroid malignan-
cies), and shows a major degree of aggressiveness with
respect to papillary cancer7. In fact, follicular cancer has
a greater rate of recurrence and is more frequently asso-
ciated with extra-glandular extension and distant meta-
stases, preferring to spread through the blood stream8,4,5.
Follicular cancer outcome is generally less favorable than
papillary prognosis.
Management of DTC
Initial management of DTC is surgical and includes
near total thyroidectomy with/or without lymph node
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dissection, followed by radioiodine 131I ablation of resid-
ual thyroid tissue9. Patients require thyroid hormone re-
placement; thyroxine is decreased serum thyroid stimu-
lating hormone (TSH) until is <0.1 mU/L. Low TSH
levels in the bloodstream reduce tumor growth rates and
reduce recurrence rates of DTC – the greater the sup-
pression of TSH the better the outcome10.
Thyroglobulin – assessment tool for follow-up
Thyroglobulin (Tg) is a 670 kDa glycoprotein made up
of two identical subunits11 and acts as a scaffold for thy-
roid hormone synthesis. It is specific for follicular-de-
rived thyroid cells12. More than 95% of papillary and
follicular carcinomas are Tg positive, even those that are
metastatic. Well-differentiated tumors generally express
more Tg than poorly differentiated tumors13. The pri-
mary use of serum Tg measurement is, however, as tu-
mor marker for patients affected by DTC6, 14,16. Serum Tg
measurement is the best means of detecting normal and
malignant thyroid tissue because there are no other
sources to falsely elevate it. Its growing role as a bio-
marker with a very high reliability is due to the fact that,
based on recently published data, the frequency of diag-
nosis of new thyroid cancer appears to be increasing, es-
pecially in women. Of high clinical interest is the issue of
Tg interference by autoantibodies, which occurs with all
immunometric methods (although radioimunoassays are
somewhat more resistant)16. Approximately 25% of pa-
tients with DTC display anti-thyroglobulin antibodies
(TgAb), compared to 10% of the general population17.
These cause measured Tg levels to be falsely low, likely
due to thyroglobulin-antibody complexes not being de-
tected18. Persistence or rising thyroglobulin antibodies
may be a marker for antigenic stimulation and thus on-
going disease17.
Long-term follow-up
Since DTC may recur at any time for years and thy-
roxine therapy is life-long, a long term follow up by se-
rum Tg measurements and ultrasonography (US) and/or
whole-body-scanning (WBS) is necessary19,20. Tg mea-
surement is then part of routinely surveillance and now
it is considered the elected biological marker for papillary
and follicular thyroid cancer, together referred to DTC21.
TgAbs should thus be quantitatively measured with each
serum Tg request, and, when present, usually invalidate
the serum Tg result.
The aim of the present study was to assess the prog-
nostic value of Tg and TgAb in patients with differenti-
ated thyroid cancer.
Patients and Methods
The study included 116 adult patients (mean age 51.2
years, range 20–81) treated for a well-differentiated thy-
roid carcinoma between 2000 and 2010. Data were retro-
spectively collected from medical records at Clinic of Nu-
clear Medicine, Clinical Center University of Sarajevo.
All patients underwent total or near total thyroidectomy
at Clinic of Oto-Rhino-Laryngology and Clinic of Oncol-
ogy and Glandular surgery, Clinical Center University of
Sarajevo. In all patients ablation with radioiodine 131I fol-
lowed postoperatively, and all patients received suppres-
sive treatment with thyroxin to maintain thyroid stimulat-
ing hormone (TSH) below 0.05mU/l. Serum thyroglobulin
(Tg) and anti-thyroglobulin antibodies (TgAb) levels were
measured preoperatively, 1 month after thyroidectomy
(before 131I treatment) and 6 (Tg1, TgAb1) and 12
months (Tg2, TgAb2) after ablation therapy. In detection
of carcinoma recurrence or disease-free status, follow-up
protocol included also ultrasonography (US) and whole-
-body-scanning (WBS). Other imaging studies such as
computed tomography (CT) and magnetic resonance im-
aging (MRI) were performed when metastasis outside
the neck was clinically suspected.
Serum levels of Tg and TgAb were assessed using the
electrochemiluminescence immunoassay (Elecsys and co-
base immunoassay analyzers), with functional sensitiv-
ity of at least 0.1 ng/ml for Tg and 10 IU/ml for TgAb.
Normal range of Tg by this method is 1.4–78 ng/ml, and
normal range of TgAb is <115 IU/ml. Stimulated Tg lev-
els after thyreoidectomy and radioiodine ablation above
5 to 10 ng/mL were considered to indicate residual or re-
current tumor, regardless of the WBS finding22, so as
threshold level of Tg for high risk for residual or recur-
rent disease we used value of 10 ng/ml.
Statistical analysis
Statistical analyses were performed using SPSS sta-
tistical software system (version 16.0, SPSS Inc, Chicago,
IL, USA). Data are presented as mean±S.E.M. Normal
distribution was tested using the Kolmogorov–Smirnov
test. Difference between groups was tested using the
t-test, while the difference in serial values were tested
with repeated measures one-way ANOVA. To test the
predictor for the recurrent disease the following vari-
ables were entered in the model: age, gender, TNM classi-
fication, tumor histology diagnosis, Tg and TgAb levels
and 131I doses received. Two-tailed p values <0.05 were
accepted as statistically significant.
Results
Baseline characteristics of the patients included in
the study are shown in Table 1. In all patients ablation
with radioiodine 131I followed thyroidectomy, a mean
dose of 81.4mCi.
Recurrent disease was confirmed in 24 patients (21%),
among them 10 papillary (42%) and 14 follicular cancers
(58%), as it is shown in Table 2.
In our study serum Tg levels measured preoperatively
and Tg levels measured before 131I therapy introduction
were significantly higher in patients with recurrent dis-
ease compared to the patients without recurrent disease
(p<0.05, Table 3). Serum Tg levels were also signifi-
cantly higher in patients with recurrent diseases mea-
sured 6 and 12 months after ablation therapy in compari-
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son with the patients without recurrent disease (p<0.05,
Table 4). However, serum TgAb levels were similar in pa-
tients with or without recurrent disease, with no statisti-
cal significance.
As threshold level for Tg measured 6 and 12 months
after radioiodine remnant ablation was used value of
10ng/ml. According to Tg threshold level (above/below)
and disease recurrence (yes/no), all patients were grouped
in 4 groups: group 1. (patients with recurrent disease
and Tg above threshold level), group 2. (patients with re-
current disease and Tg below threshold level), group 3.
(patients with no evidence of disease and Tg above thresh-
old level) and group 4. (patients with no evidence of dis-
ease and Tg below threshold). Mean values of Tg mea-
sured before thyroidectomy and before 131I therapy com-
pared with mean values of Tg measured 6 and 12 month
after, showed significant correlation within the groups 1,
3 and 4 (p<0.05, Table 5), while mean values of TgAb did
not show any significant correlation within the same
groups (Table 6).
A significant association between serum Tg levels
(measured preoperatively and postoperatively) and re-
current diseases, as well as between 131I doses received
and recurrent diseases was observed in our study. How-
ever, in multivariate regression analysis only Tg levels
measured 12 months after the therapy (Tg2) remained a
significant predictor of recurrent disease (Exp(B)=1.165,
p=0.008, Table 7).
Discussion and Conclusion
The study found that DTC had highest incidence in
women (3.3:1), as it confirmed Haselkorn et al23. Folli-
cular cancer is less frequent than papillary type, but it
J. Alagi}-Smailbegovi} et al.: Thyroglobulin and Anti-Thyroglobulin Antibodies, Coll. Antropol. 36 (2012) Suppl. 2: 33–38
35
TABLE 1
CHARACTERISTICS OF THE PATIENTS
N (%)





Papillary cancer 66 (57)












CHARACTERISTICS OF THE PATIENTS WITH RECURRENT
DISEASE
N (%)





Papillary cancer 10 (42)
Follicular cancer 14 (58)
Total 24 (100)
TABLE 3
VALUES OF THYROGLOBULIN AND ANTI-THYROGLOBULIN-
-ANTIBODIES BEFORE SURGERY AND BEFORE 131I TREATMENT,
AND ITS CORELATION BETWEEN PATIENTS WITH NO
EVIDENCE OF DISEASE AND PATIENTS WITH RECURRENCE
N X SEM p-value
Tg
presurgical
NED 67 160.8 35.2 0.037*
REC 20 381.8 94.0
TgAb
presurgical
NED 49 193.6 80.2 NS
REC 16 181.2 59.2
Tg
before 131I
NED 91 9.3 3.1 0.023*
REC 22 190.8 73.8
TgAb
before 131I
NED 85 69.5 26.2 NS
REC 20 31.3 9.7
Tg – thyroglobulin (ng/ml), TgAb – anti-thyroglobulin antibody
(IU/ml), 131I – radioiodine treatment, NED – no evidence of dis-
ease, REC – recurrence, SEM – standard error of the mean, NS –
no significant, *significant correlation (p<0.05)
TABLE 4
VALUES OF THYROGLOBULIN AND ANTI-THYROGLOBULIN-
-ANTIBODIES 6 AND 12 MONTHS AFTER ABLATION, AND ITS
CORELATION BETWEEN PATIENTS WITH NO EVIDENCE OF
DISEASE AND PATIENTS WITH RECURRENCE
N X SEM p-value
Tg1
NED 88 6.06 1.3
REC 19 336.4 92.6 0.002
TgAb1
NED 65 111.0 39.3
REC 15 129.3 41.7 NS
Tg2
NED 83 3.2 0.9
REC 16 369.0 111.3 0.005
TgAb2
NED 68 77.5 38.7
REC 14 51.7 20.9 NS
Tg1 – thyroglobulin 6 months after radioiodine remnant abla-
tion, TgAb1 – anti-thyroglobulin antibody 6 months after radio-
iodine remnant ablation, Tg2 – thyroglobulin 12 months after
radioiodine remnant ablation, TgAb2 – anti-thyroglobulin anti-
body 12 months after radioiodine remnant ablation, NED – no
evidence of disease, REC – recurrence, SEM – standard error of
the mean, NS – no significant, *significant correlation (p<0.05)
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also has generally less favorable outcome5, as the study
found higher incidence of recurrent disease in patients
with follicular cancer. We investigated whether serum Tg
determination before surgery for DTC may have any
prognostic value, and found that serum Tg levels mea-
sured preoperatively were significantly higher in pa-
tients with recurrent disease compared to the patients
without recurrent disease (p<0.05). Gibelli24 et al found
that pre-operative assessment of serum Tg may identify
patients who might present recurrence without increased
Tg, and in whom standard follow-up by monitoring Tg
serum levels is inadequate. However, a high Tg level be-
fore surgery does not indicate that a tumor is pre-
sent25,26, a high serum Tg concentrations may be due to
an abnormally large thyroid, excessive thyroid stimula-
tion, or physical damage to the thyroid24, and this study
failed to show any prognostic value of presurgical serum
Tg determination that consequently should not be mea-
sured. All patients underwent surgical procedure which
includes total or near total thyroidectomy with/or with-
out neck lymph node dissection, followed by radioiodine
131I ablation of residual thyroid tissue, as it is estimated
as treatment of choice in management of DTC9,10,27. Al-
though DTC is characterized by an excellent prognosis
after thyroidectomy and radioiodine ablation, recur-
rences occur often even many years after this initial
therapy10,28, recurrent disease does occur in approxi-
mately 20–40% of patients29. During one year of fol-
low-up in our study, in a total of 24 patients (21%) recur-
rent disease were confirmed by ultrasonography and
whole-body-scanning, mostly, and follicular cancers showed
a major degree of aggressiveness with respect to papil-
lary cancer, as it confirmed by Pacini et al7. The clinical
and economical relevance of optimal follow-up with accu-
rate diagnostic testing is crucial considering the large
population of patients in life long follow-up for DTC
world-wide. Traditionally, the cornerstone of follow-up is
serum Tg measurement. Optimal sensitivity is reached
when Tg is measured during thyrotropin (TSH) stimula-
tion because TSH promotes Tg synthesis28. Changes in
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TABLE 5











1. 23 401.7±96.86 199.9±76.8 354.8±95.9 393.6±116.0 <0.05*
2. 1 – – – – –
3. 15 189.6±95.7 33.3±17.5 25.6±4.9 13.9±4.2 <0.05*
4. 77 154.5±37.8 4.6±0.64 2.1±0.35 0.85±0.19 <0.05*
Tg – thyroglobulin (ng/ml), 131I – radioiodine treatment, Tg1 – thyroglobulin 6 months after radioiodine remnant ablation, Tg2 – thy-
roglobulin 12 months after radioiodine remnant ablation, *significant correlation (p<0.05)
TABLE 6












1. 23 181.2±59.17 31.2±10.2 130.8±44.7 53.6±22.5 NS
2. 1 – – – – –
3. 15 16.4±3.1 13.3±0.9 39.3±20.9 21.3±5.6 NS
4. 77 223.1±92.9 78.7±30.3 125.6±46.9 88.3±46.1 NS
TgAb – anti-thyroglobulin antibody (IU/ml), 131I – radioiodine treatment, TgAb1 – anti-thyroglobulin antibody 6 months after radio-
iodine remnant ablation, TgAb2 – anti-thyroglobulin antibody 12 months after radioiodine remnant ablation, NS – no significant
TABLE 7
MULTIVARIATE REGRESSION ANALYSIS OF ASSOCIATION
BETWEEN THE VARIOUS PARAMETERS (AGE, TUMOR
HISTOLOGY, 131I DOSE, SERUM THYROGLOBULIN BEFORE




Papillary cancer 0.738 0.588
Follicular cancer 1.000 0.000
Tg presurgical 0.792 1.001
Tg before 131I 0.381 0.941




Tg – thyroglobulin (ng/ml), 131I – radioiodine treatment, Tg1 –
thyroglobulin 6 months after radioiodine remnant ablation, Tg2
– thyroglobulin 12 months after radioiodine remnant ablation,
*significant correlation (p<0.05)
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the Tg level over time (six months or yearly intervals)
are more important than any one Tg result. After sur-
gery, blood samples are usually taken for Tg measure-
ment while the patient is taking their daily dose of thy-
roxine medication (TSH low)26. Current clinical
guidelines are based on immunometric assays with a
functional sensitivity of 1ng/mL27. Using assays of this
sensitivity, a detectable Tg on suppressive therapy reli-
ably indicates ongoing disease, although a negative re-
sult does not. Stimulation of latent thyroid cancer cells to
produce and secrete Tg (so-called stimulated Tg) can
therefore alert the clinician to the need for further diag-
nostic evaluation or empiric treatment. Stimulated Tg
levels above 5 to 10ng/mL were considered to indicate re-
sidual or recurrent tumor, regardless of the WBS
finding22,30–32, and our study found significant correla-
tion between higher values of Tg1 and Tg2 (values above
than 10ng/ml measured 6 and 12 months after ablation
therapy, respectively) and recidives of cancer (p<0.05), in
comparison with patients with no evidence of disease.
However, in multivariate regression analysis between
the various parameters (age, gender, tumor histology,
dose of 131I, Tg and TgAb measured before and after
treatment), only Tg levels measured 12 months after the
therapy (Tg2) remained a significant predictor of recur-
rent disease (p= 0.008). On the other hand, serum TgAb
levels did not have any statistical significance. For pa-
tients with a negative stimulated Tg one year after initial
treatment, the chance of a subsequent positive result
during follow-up is low – thus one stimulated test may be
adequate in this group33. In those with detectable stimu-
lated Tg, serial evaluation may be useful27,33.
In conclusion, although presurgical serum Tg level is
no specific for DTC and could not have significant prog-
nostic value, serum Tg level after surgery is an excellent
biological marker of persistent or recurrent DTC during
first year of follow-up. In fact, detection of stimulated Tg
levels above threshold after total thyroid ablation sug-
gests recurrent disease, and can therefore alert the clini-
cian to the need for further diagnostic evaluation or em-
piric treatment.
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VA@NOST ODRE\IVANJA TIREOGLOBULINA I ANTITIREOGLOBULINSKIH PROTUTIJELA KOD
DIFERENCIRANOG CARCINOMA [TITNJA^E
S A @ E T A K
Difencirani karcinom {titnja~e uklju~uje papilarni i folikularni. Lije~enje izbora je naj~e{}e totoalna ili subtotalna
tiroidektomija, nakon koje slijedi radiojodna terapija i dugotrajna supstitucija hormona. Usprkos odli~noj prognozi bo-
lest se ponavlja u 20–40% bolesnika. Pra}enje bolesnika se obi~no bazira na mjerenju cirkuliraju}eg tireoglobulina.
Retrospektivna studija je provedena na 116 bolesnika (66 papilarnih i 50 folikularnih carcinoma, srednja dob 51.2
godine) kod kojih je u~injena totalna ili skoro totalna tiroidektomija i radiojodna terapija. Preoperativno su mjereni
tireoglobulin i anti-tiroglobulinska protutijela (TgAb), zatim 1 mjesec nakon tiroidektomije (prije radiojoda) te 6 i 12
mj. nakon ablacije. Kroz pra}enje tijekom 1 godine kod ukupno 24 bolesnika se pojavila rekurentna bolest (21%), potvr-
|ena ultrazvukom i scintigrafijom. Na|ena je zna~ajna korerlacija izme|u serumskog tireoglobulina (preoperativno i
postoperativno) i rekurentne bolesti (p<0–05), dok razina TbAg nije pokazala statisti~ki zna~aj. Me|utim, razina Tg
nakon 12 mjeseci (Tg2) je ostala zna~ajan pokazatelj rekurentne bolesti (p=0.008). Iako visok Tg prije kirurgije ne
pokazuje da je tumor prisutan, u postoperativnom periodu i nakon ablativne terapije Tg ima prediktivnu vrijednost i
preporu~ljivo je njegovo povremeno mjerenje.
J. Alagi}-Smailbegovi} et al.: Thyroglobulin and Anti-Thyroglobulin Antibodies, Coll. Antropol. 36 (2012) Suppl. 2: 33–38
38
U:\coll-antropolo\coll-antro-(Suppl 2)-2012\01 Alagic.vp
6. prosinac 2012 15:45:09
Color profile: Generic CMYK printer profile
Composite  150 lpi at 45 degrees
